drugset / Trial / NCT00075621
Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Autologous stem cell transplantation may be effective treatment for primary systemic (AL) amyloidosis. PURPOSE: This phase II trial is studying how well tandem (two) autologous stem cell transplantation works in treating patients with primary systemic (AL) amyloidosis.
Timeline
- Start
- 2000-08
- Primary completion
- 2005-06
- Completion
- 2020-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 200 mg/kg | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | 16 mg/kg | Subcutaneous |